China’s strong economic growth and healthcare investments generate success for CPhI

CPhI China 2013, which took place on 25–27 June at the Shanghai New International Expo Centre, was the most successful exhibition to date, according to organisers CPhI and UBM Live.

Attendance rates far exceeded expectation and CPhI and P-MEC China, alongside co-located events BioPh, ICSE, InnoPack, hosted a record-breaking more than 2,400 companies, both local and international, and attracted more than 30,000 visitors from 133 countries throughout the world.

In response to the implementation of China’s ‘five-year plan’, CPhI China 2013 saw a strong focus on research and development with LABWorld, BioPharma and ICSE all contained in one hall.

R&D investments in China have been at a high throughout 2013 – it has been estimated that growth in investment within this area matches that of the US.

The Chinese government's 'five-year plan' targets pharmaceutical R&D as a key initiative, with financial and beneficial incentives being offered to encourage R&D activities within the country. These include exemption from import customs duty on R&D equipment and a reduced income tax rate. In light of this, the R&D focus at CPhI China 2013 provided an informative update on the efforts being made by the government to facilitate innovation within the country.

The R&D focus at CPhI China 2013 provided an informative update on the efforts being made by the government to facilitate innovation

The 'China and World' Medical Forum at the show proved insightful and valuable for attendees. Having received substantial support from a team of speakers from government and leading pharmaceutical companies, the forum showcased topical seminars and conferences. These covered the latest policies and regulations within the pharmaceutical industry and the practical applications of new technology.

Furthermore, the Buyer Sourcing Event, with more than 60 buyers, 280 sessions and over 90% successful match rate, has provided a catalyst for increased business connections in the region.

Chris Kilbee, CPhI Pharma Group Director at UBM Live, said: 'The Chinese pharmaceutical industry is now the third-largest in the world and is ever growing – it is predicted to expand at the annual rate of 12% from 2013 to 2020. Having witnessed a shift in focus to R&D by China, CPhI China 2013 was designed to reflect these widespread changes. The event was undoubtedly a success for both UBM Live, CCMHPIE and our attendees and, consequently, over 40% of exhibitors present have already registered for next year.'

CPhI China 2014 will return alongside co-located events ICSE, BioPh, P-MEC, InnoPack and Labworld, on 26–28 June 2014 at the Shanghai New International Expo Centre. The exhibition will increase its scale and focus on biopharmaceutical R&D, with BioPh China and ICSE China making up an integral part of the exhibition.

A further main focus for next year will be natural extracts, in which exhibiting companies will occupy more than one hall.